InterVenn Biosciences requests that their press release NewsItemId: 20211112005301 “InterVenn Presents Results Detailing Glycoproteomic Signature Predictive of Response to Immune Checkpoint Inhibitor Treatment in Advanced Non-Small Cell Lung Cancer at American Society for Immunotherapy of Cancer” be killed.
--(BUSINESS WIRE)-- InterVenn Biosciences requests that their press release NewsItemId: 20211112005301 “InterVenn Presents Results Detailing Glycoproteomic Signature Predictive of Response to Immune Checkpoint Inhibitor Treatment in Advanced Non-Small Cell Lung Cancer at American Society for Immunotherapy of Cancer” be killed.
The release was issued prematurely by InterVenn Biosciences.
A replacement release will be issued later today.
Source:
View this news release online at:
http://www.businesswire.com/news/home/20211112005301/en